{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T12:01:28Z","timestamp":1784894488907,"version":"3.55.0"},"reference-count":62,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Deanship of Research and Graduate studies at King Khalid University for funding this work through Large Research Project","award":["RGP2\/45\/47"],"award-info":[{"award-number":["RGP2\/45\/47"]}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>The introduction of immune checkpoint inhibitors has transformed therapeutic strategies for multiple solid malignancies, with pembrolizumab emerging as a key treatment option. It is used as monotherapy in patients with high programmed death-ligand 1 (PD-L1) expression and in combination with chemotherapy in broader clinical settings. Although survival benefits are well established, understanding the impact of these treatment approaches on health-related quality of life (HRQoL) is essential for long-term cancer care. This review aims to summarize and compare HRQoL outcomes in patients with solid tumors receiving pembrolizumab monotherapy versus combination chemotherapy, while considering disease-specific PD-L1 scoring systems (tumor proportion score [TPS] and combined positive score [CPS]) and expression thresholds to support personalized treatment strategies. This narrative review synthesized evidence from randomized controlled trials, observational studies, meta-analyses, and real-world analyses identified through literature searches of major databases, including PubMed, Scopus, and Google Scholar, focusing on studies reporting HRQoL outcomes in patients receiving pembrolizumab-based therapies. A total of 64 studies were included in this narrative review. Across the included studies, HRQoL findings were heterogeneous because of differences in assessment instruments, follow-up time points, and endpoint definitions. Pembrolizumab monotherapy was commonly associated with HRQoL maintenance, delayed deterioration, or improvement in selected HRQoL domains, particularly in disease settings where pembrolizumab monotherapy is indicated for patients with higher PD-L1 expression. In contrast, combination chemotherapy was frequently associated with an early decline in HRQoL attributable to treatment-related toxicity, followed by stabilization or partial recovery, reflecting long-term functional preservation in patients achieving disease control. Overall, HRQoL outcomes varied according to tumor type, PD-L1 scoring framework, baseline symptom burden, assessment timing, and the specific HRQoL endpoint evaluated. Pembrolizumab-based therapy plays a pivotal role in modern oncology by improving survival while maintaining favorable HRQoL outcomes in appropriately selected patients. However, direct comparisons between pembrolizumab monotherapy and combination chemotherapy should be interpreted cautiously because differences in HRQoL instruments, assessment timing, endpoint definitions, and disease-specific PD-L1 assessment methodologies may contribute to the observed findings. Disease-specific PD-L1-guided treatment selection may help balance therapeutic efficacy with patient well-being; however, HRQoL findings should be interpreted within tumor-specific PD-L1 frameworks rather than as evidence of a uniform PD-L1-driven effect across all solid tumors. Future research should prioritize prospective head-to-head HRQoL comparisons using standardized HRQoL instruments, harmonized endpoint definitions, consistent assessment schedules, and disease-specific PD-L1-stratified analyses across tumor types to optimize patient-centered treatment strategies.<\/jats:p>","DOI":"10.3389\/fmed.2026.1890061","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T11:10:19Z","timestamp":1784891419000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["PD-L1\u2013stratified health-related quality of life in solid tumors: pembrolizumab versus chemotherapy\u2014a narrative review"],"prefix":"10.3389","volume":"13","author":[{"given":"Eman","family":"Shorog","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, College of Pharmacy, King Khalid University","place":["Abha, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lavanya","family":"Selvaraj","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, PSG College of Pharmacy","place":["Coimbatore, Tamil Nadu, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geetha","family":"Kandasamy","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, College of Pharmacy, King Khalid University","place":["Abha, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tariq Eidhah","family":"Alzahrani","sequence":"additional","affiliation":[{"name":"Saudi Society of Clinical Pharmacy","place":["Riyadh, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alhanouf F.","family":"Almousa","sequence":"additional","affiliation":[{"name":"King Faisal Specialist Hospital and Research Centre","place":["Riyadh, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maram A.","family":"Alenazi","sequence":"additional","affiliation":[{"name":"Pharmaceutical Care Services, King Salman Specialist Hospital, Hail Health Cluster, Ministry of Health","place":["Hail, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanan","family":"Alshareef","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Faculty of Pharmacy, University of Tabuk","place":["Tabuk, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanthanalakshmi Siva","family":"Basavan","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, PSG College of Pharmacy","place":["Coimbatore, Tamil Nadu, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,24]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","article-title":"Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study","volume":"394","author":"Burtness","year":"2019","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1001\/jamaoncol.2020.3370","article-title":"Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the KEYNOTE-062 phase 3 randomized clinical trial","volume":"6","author":"Shitara","year":"2020","journal-title":"JAMA Oncol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1093\/oncolo\/oyae087","article-title":"Health-related quality-of-life analysis from KEYNOTE-590: pembrolizumab plus chemotherapy versus chemotherapy for advanced esophageal cancer","volume":"29","author":"Mansoor","year":"2024","journal-title":"The Oncologist."},{"key":"ref5","volume-title":"Goodman & Gilman\u2019s the Pharmacological basis of Therapeutics","author":"Brunton","year":"2018"},{"key":"ref6","year":"2023"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"D1074","DOI":"10.1093\/nar\/gkx1037","article-title":"DrugBank 5.0: a major update to the DrugBank database for 2018","volume":"46","author":"Wishart","year":"2018","journal-title":"Nucleic Acids Res"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in microsatellite-instability\u2013high advanced colorectal cancer","volume":"383","author":"Andr\u00e9","year":"2020","journal-title":"N Engl J Med"},{"key":"ref9","volume-title":"FDA Approves Pembrolizumab for Adults and children with TMB-H solid Tumors","year":"2020"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1200\/JCO.19.03136","article-title":"Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for metastatic nonsquamous non-small-cell lung cancer","volume":"38","author":"Gadgeel","year":"2020","journal-title":"J Clin Oncol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1093\/jnci\/djad240","article-title":"Health-related quality of life with pembrolizumab plus chemotherapy vs placebo plus chemotherapy for advanced triple-negative breast cancer: KEYNOTE-355","volume":"116","author":"Cescon","year":"2024","journal-title":"J Natl Cancer Inst"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1056\/NEJMoa2202809","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for advanced triple-negative breast cancer","volume":"387","author":"Cortes","year":"2022","journal-title":"N Engl J Med"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1200\/JCO.1993.11.3.570","article-title":"The functional assessment of Cancer therapy scale: development and validation of the general measure","volume":"11","author":"Cella","year":"1993","journal-title":"J Clin Oncol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J Clin Oncol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"e011760","DOI":"10.1136\/jitc-2025-011760","article-title":"Phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: pancreatic neuroendocrine neoplasm (PNEN) cohort","volume":"13","author":"Patel","year":"2025","journal-title":"J Immunother Cancer"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1200\/JCO.2017.76.9562","article-title":"Health-related quality-of-life analysis from KEYNOTE-045: a phase III study of pembrolizumab versus chemotherapy for previously treated advanced urothelial cancer","volume":"36","author":"Vaughn","year":"2018","journal-title":"J Clin Oncol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1016\/S1470-2045(17)30690-3","article-title":"Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial","volume":"18","author":"Brahmer","year":"2017","journal-title":"Lancet Oncol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/s41571-021-00473-5","article-title":"PD-L1 as a biomarker of response to immune-checkpoint inhibitors","volume":"18","author":"Doroshow","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1192762","DOI":"10.3389\/fmed.2023.1192762","article-title":"Immune checkpoint inhibitors efficacy across solid cancers and the utility of PD-L1 as a biomarker of response: a systematic review and meta-analysis","volume":"10","author":"Fitzsimmons","year":"2023","journal-title":"Front Med"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.ejca.2021.10.005","article-title":"Health-related quality of life in cancer patients treated with immune checkpoint inhibitors in randomised controlled trials: a systematic review and meta-analysis","volume":"159","author":"Boutros","year":"2021","journal-title":"Eur J Cancer"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"e2226252","DOI":"10.1001\/jamanetworkopen.2022.26252","article-title":"Association of anticancer immune checkpoint inhibitors with patient-reported outcomes assessed in randomized clinical trials: a systematic review and meta-analysis","volume":"5","author":"Pala","year":"2022","journal-title":"JAMA Netw Open"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"56","DOI":"10.14740\/gr2029","article-title":"Procalcitonin as a predictor of mortality in patients with severe acute pancreatitis","volume":"18","author":"Ramirez-Gonzalez","year":"2025","journal-title":"Gastroenterol Res"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1186\/s12957-022-02800-1","article-title":"Quality of life in patients with non-small cell lung cancer treated with PD-1\/PD-L1 inhibitors: a systematic review and meta-analysis","volume":"20","author":"Liu","year":"2022","journal-title":"World J Surg Onc"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.ejca.2017.08.032","article-title":"Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma","volume":"86","author":"Petrella","year":"2017","journal-title":"Eur J Cancer"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.annonc.2022.11.012","article-title":"Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up","volume":"34","author":"Balar","year":"2023","journal-title":"Ann Oncol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1200\/JCO.21.00174","article-title":"Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non\u2013small-cell lung Cancer with PD-L1 tumor proportion score \u2265 50%","volume":"39","author":"Reck","year":"2021","journal-title":"JCO"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1007\/s10120-021-01200-w","article-title":"Health-related quality of life in advanced gastric\/gastroesophageal junction cancer with second-line pembrolizumab in KEYNOTE-061","volume":"24","author":"Van Cutsem","year":"2021","journal-title":"Gastric Cancer"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1002\/cncr.33317","article-title":"Health-related quality-of-life impact of pembrolizumab versus best supportive care in previously systemically treated patients with advanced hepatocellular carcinoma: KEYNOTE-240","volume":"127","author":"Ryoo","year":"2021","journal-title":"Cancer"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"e70106","DOI":"10.1002\/psp4.70106","article-title":"A model-based meta-analysis of pembrolizumab effects on patient-reported quality of life: advancing patient-centered oncology drug development","volume":"15","author":"Zou","year":"2026","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/S1470-2045(19)30801-0","article-title":"Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial","volume":"21","author":"Garassino","year":"2020","journal-title":"Lancet Oncol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1200\/JCO.22.01990","article-title":"Pembrolizumab plus chemotherapy in squamous non-small-cell lung cancer: patient-reported outcomes from KEYNOTE-407","volume":"148","author":"Novello","year":"2021","journal-title":"Eur J Cancer"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1080\/1750743X.2026.2665031","article-title":"Pembrolizumab combined with chemotherapy for advanced or metastatic non-small cell lung cancer with low PD-L1 expression: a systematic review and meta-analysis of randomized controlled trials","volume":"18","author":"Vatvani","year":"2026","journal-title":"Immunotherapy"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1375136","DOI":"10.3389\/fimmu.2024.1375136","article-title":"Comparative long-term outcomes of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy as first-line therapy for metastatic non-small-cell lung cancer: a systematic review and network meta-analysis","volume":"15","author":"Huang","year":"2024","journal-title":"Front Immunol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"8012","DOI":"10.1200\/JCO.2024.42.16_suppl.8012","article-title":"Health-related quality of life (HRQoL) outcomes from the randomized, double-blind phase 3 KEYNOTE-671 study of perioperative pembrolizumab for early-stage non-small-cell lung cancer (NSCLC)","volume":"42","author":"Garassino","year":"2024","journal-title":"J Clin Oncol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"e0307800","DOI":"10.1371\/journal.pone.0307800","article-title":"Efficacy, safety, and patient-reported outcome of immune checkpoint inhibitor in gynecologic cancers: a systematic review and meta-analysis of randomized controlled trials","volume":"19","author":"Kusuma","year":"2024","journal-title":"PLoS One"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s11136-025-04109-4","article-title":"Analysis of quality-adjusted survival time without symptoms or toxicity for pembrolizumab plus chemotherapy as treatment for previously untreated participants with advanced or metastatic esophageal cancer","volume":"35","author":"Zhang","year":"2026","journal-title":"Qual Life Res"},{"key":"ref39","first-page":"26","author":"McArthur","year":"2025"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.3390\/healthcare12151496","article-title":"Effects of immunotherapy on quality-of-life outcomes in patients with gastroesophageal cancers: a Meta-analysis of randomized controlled trials","volume":"12","author":"Gupta","year":"2024","journal-title":"Healthcare"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/S1470-2045(21)00064-4","article-title":"Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial","volume":"22","author":"Andre","year":"2021","journal-title":"Lancet Oncol"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"3917","DOI":"10.3390\/cancers17243917","article-title":"Health-related quality of life in the era of immune checkpoint blockade: what do patient-reported outcomes reveal?","volume":"17","author":"Dunker","year":"2025","journal-title":"Cancer"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1016\/j.annonc.2024.08.2330","article-title":"Pembrolizumab versus ipilimumab for advanced melanoma: 10-year follow-up of the phase III KEYNOTE-006 study","volume":"35","author":"Long","year":"2024","journal-title":"Ann Oncol"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"4918","DOI":"10.3390\/jcm13164918","article-title":"Real-world comparison of health-related quality of life associated with use of immune-checkpoint inhibitors in oncology patients","volume":"13","author":"Alwhaibi","year":"2024","journal-title":"JCM"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"105073","DOI":"10.1016\/j.esmoop.2025.105073","article-title":"Real-world comparison of pembrolizumab alone and combined with chemotherapy in metastatic lung adenocarcinoma patients with PD-L1 expression \u226550%","volume":"10","author":"Hektoen","year":"2025","journal-title":"ESMO Open"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1093\/annonc\/mdz127","article-title":"Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up","volume":"30","author":"Fradet","year":"2019","journal-title":"Ann Oncol"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.ygyno.2022.06.005","article-title":"Health-related quality of life with pembrolizumab monotherapy in patients with previously treated advanced microsatellite instability high\/mismatch repair deficient endometrial cancer in the KEYNOTE-158 study","volume":"166","author":"O\u2019Malley","year":"2022","journal-title":"Gynecol Oncol"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.oraloncology.2022.105815","article-title":"Health-related quality of life in KEYNOTE-048: pembrolizumab alone or with chemotherapy versus cetuximab plus chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma","volume":"31","author":"Rischin","year":"2020","journal-title":"Ann Oncol"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1200\/JCO.2004.06.078","article-title":"Measuring quality of life in routine oncology practice improves communication and patient well-being: a randomized controlled trial","volume":"22","author":"Velikova","year":"2004","journal-title":"J Clin Oncol"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non\u2013small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"3262","DOI":"10.3390\/cancers17193262","article-title":"Optimizing anti-PD1 immunotherapy: an overview of pharmacokinetics, biomarkers, and therapeutic drug monitoring","volume":"17","author":"Monteiro","year":"2025","journal-title":"Cancers (Basel)"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1200\/JCO.2014.57.9334","article-title":"Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials","volume":"33","author":"Di Maio","year":"2015","journal-title":"J Clin Oncol"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.jtho.2016.11.2228","article-title":"PD-L1 immunohistochemistry assays for lung Cancer: results from phase 1 of the blueprint PD-L1 IHC assay comparison project","volume":"12","author":"Hirsch","year":"2017","journal-title":"J Thorac Oncol"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/modpathol.2017.188","article-title":"Concordance study of PD-L1 expression in primary and metastatic bladder carcinomas: comparison of four commonly used antibodies and RNA expression","volume":"31","author":"Tretiakova","year":"2018","journal-title":"Mod Pathol"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"e83","DOI":"10.1016\/S1470-2045(19)30790-9","article-title":"International standards for the analysis of quality-of-life and patient-reported outcome endpoints in cancer randomised controlled trials: recommendations of the SISAQOL consortium","volume":"21","author":"Coens","year":"2020","journal-title":"Lancet Oncol"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"e510","DOI":"10.1016\/S1470-2045(16)30510-1","article-title":"Analysing data from patient-reported outcome and quality of life endpoints for cancer clinical trials: a review of current practice and future directions","volume":"17","author":"Bottomley","year":"2016","journal-title":"Lancet Oncol"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"e40826","DOI":"10.1097\/MD.0000000000040826","article-title":"Pembrolizumab alone or combined with chemotherapy versus chemotherapy for the treatment of metastatic cancer: a meta-analysis of randomized clinical trials","volume":"103","author":"Yue","year":"2024","journal-title":"Medicine (Baltimore)"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s13000-016-0545-8","article-title":"Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma","volume":"11","author":"Rebelatto","year":"2016","journal-title":"Diagn Pathol"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"e000783","DOI":"10.1136\/bmjonc-2025-000783","article-title":"Patient-reported outcomes (PROs) in clinical trials and in clinical practice: report from the XXI national conference of the Italian Association of Medical Oncology (AIOM)","volume":"4","author":"Puccini","year":"2025","journal-title":"BMJ Oncology"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1200\/jco.1998.16.1.139","article-title":"Interpreting the significance of changes in health-related quality-of-life scores","volume":"16","author":"Osoba","year":"1998","journal-title":"J Clin Oncol"},{"key":"ref61","volume-title":"Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics: Guidance for Industry","year":"2018"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41568-019-0116-x","article-title":"The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy","volume":"19","author":"Havel","year":"2019","journal-title":"Nat Rev Cancer"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1890061\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T11:10:21Z","timestamp":1784891421000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1890061\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,24]]},"references-count":62,"alternative-id":["10.3389\/fmed.2026.1890061"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1890061","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,24]]},"article-number":"1890061"}}